Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.

The trial demonstrated a marginally significant reduction in the risk of relapse compared with GC alone (relapse-free survival rate at 12 months: 48% vs 31%; p=0.049) and a longer median duration of remission (9.9 months vs 3.9 months; p=0.023), without increased toxicity.

also in 26,082 other papers